PACT Pharma

Stefanie Mandl, Ph.D.

Chief Scientific Officer

Dr. Mandl has been with PACT since the inception and has been intimately involved in the development of PACT’s platform technologies and personalized TCR-T cell Therapies.

Dr. Mandl has extensive experience in the development of immunotherapies for the treatment of cancer and infectious disease. Prior to PACT, she was the Senior Director, Immunology at Cidara Therapeutics, where she led the Immunology group characterizing the functional activity of a new generation of multifunctional immunotherapeutic agents for the treatment of cancer and infectious diseases developed using the CloudbreakTM platform approach. Before Cidara, Stefanie worked 9 years at Bavarian Nordic, most recently as the Director, Pre-clinical Oncology Research leading the development of poxvirus-based active immunotherapies for the treatment of cancer.

Dr. Mandl’s experience in cancer immunotherapy began in Berlin, where she received her MS in Biology from Freie Universität Berlin, she then earned her PhD in Immunology at the University of California San Francisco and trained as a postdoctoral fellow at Stanford University.